PAREXEL Appoints Four Executives to Senior Leadership Team
01 August 2016 - 11:00PM
Business Wire
PAREXEL International Corporation (NASDAQ: PRXL), a leading
global biopharmaceutical services provider, today announced the
appointment of four company executives to its senior-most
leadership team, the Business Review Committee:
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160801005138/en/
David Godwin, Senior Vice President,
Global Business Development (Photo: Business Wire)
- David Godwin, Senior Vice President,
Global Business Development
- Michelle Graham, Senior Vice President
and Chief Human Resources Officer
- Sy Pretorius, M.D., Senior Vice
President and Chief Scientific Officer
- Joshua Schultz, Senior Vice President,
Worldwide Head of PAREXEL Access
“PAREXEL has a history of growth, innovation and leadership that
spans more than 30 years, and these leaders have played an
important role in our success,” said Josef von Rickenbach,
Chairman and Chief Executive Officer, PAREXEL. “Our corporate
strategy is to enhance our leadership in the biopharmaceutical
services industry by focusing on our core business and capturing
new growth from adjacent markets. We will leverage the expertise of
these senior leaders to implement our strategic objectives and
further transform PAREXEL, positioning the Company for future
growth.”
Mr. Godwin joined PAREXEL in 1989 and is responsible for the
business development efforts for many of the Company’s services. He
will continue to manage global business development
initiatives.
Ms. Graham joined PAREXEL in 2015 and is responsible for the
design and launch of the Company’s people strategy, talent agenda
and refined Human Resources operating model. She will continue to
manage the company’s Human Resources function, including talent
acquisition, learning and development and organizational
development as well as be responsible for the company’s Diversity
and Inclusion programs.
Dr. Pretorius joined PAREXEL in 1996 and previously held
leadership roles in various countries. He serves as Chief
Scientific Officer and works closely with clients to design and
optimize drug and device development strategies as well as find,
evaluate and purchase assets. He will continue to be responsible
for the overall leadership of several service offerings, including
PAREXEL’s global Early Phase business, Global Medical Services,
Quantitative Clinical Development and Genomic Medicine.
Mr. Schultz joined PAREXEL in 2005 and oversees the global Late
Phase business, which provides clinical research services in the
peri/post-approval phases, including IIIb/IV clinical trials,
observational research, market access, medical communications and
patient safety services. He will continue to lead PAREXEL
Access.
About PAREXEL International
PAREXEL International Corporation is a leading global
biopharmaceutical services company, providing a broad range of
expertise-based clinical research, consulting, medical
communications, and technology solutions and services to the
worldwide pharmaceutical, biotechnology and medical device
industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, and
reimbursement. PAREXEL Informatics provides advanced technology
solutions, including medical imaging, to facilitate the clinical
development process. Headquartered near Boston, Massachusetts,
PAREXEL has offices in 82 locations in 51 countries around the
world, and had approximately 18,450 employees in the third quarter.
For more information about PAREXEL International, visit
www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its
affiliates.
This release contains “forward-looking” statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the foregoing,
the words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. Such
factors and others are discussed in the section entitled “Risk
Factors” of the Company’s most recent Annual Report on Form 10-K
and subsequent quarterly reports on Form 10-Q filed with the
Securities and Exchange Commission, which “Risk Factors” discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company’s
estimates or views as of any date subsequent to the date of this
press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160801005138/en/
MediaCristi Barnett, PAREXEL+1
781-434-4019Cristi.Barnett@PAREXEL.comorInvestorsRon
Aldridge, PAREXEL International+1
781-434-4753Ron.Aldridge@parexel.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Apr 2024 to May 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From May 2023 to May 2024